When Merck KGaA presented its financials for 2021 earlier this month, it was striking to see that a number of drugs that got their first approvals last century were still making very healthy contributions to the German group's sales.
Merck KGaA Healthcare Head Happy With Old And New Mix
Pipeline Will Augment Established Strong Sellers
The German firm’s pharma chief Peter Guenter tells Scrip that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.
More from Leadership
• By
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.